MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma
about
TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer: A research based on bioinformatics analysisTargeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells.
P2860
MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MTOR inhibition reversed drug ...... lotinib in lung adenocarcinoma
@en
MTOR inhibition reversed drug ...... otinib in lung adenocarcinoma.
@nl
type
label
MTOR inhibition reversed drug ...... lotinib in lung adenocarcinoma
@en
MTOR inhibition reversed drug ...... otinib in lung adenocarcinoma.
@nl
prefLabel
MTOR inhibition reversed drug ...... lotinib in lung adenocarcinoma
@en
MTOR inhibition reversed drug ...... otinib in lung adenocarcinoma.
@nl
P2093
P2860
P356
P1433
P1476
MTOR inhibition reversed drug ...... lotinib in lung adenocarcinoma
@en
P2093
Hongqing Zhuang
Joe Y Chang
Zhiyong Yuan
P2860
P304
84688-84694
P356
10.18632/ONCOTARGET.12423
P407
P577
2016-10-04T00:00:00Z